HUE054694T2 - Szubsztituált aminpurin vegyületek, ezek összetételei, és az ezekkel végzett kezelések módszerei - Google Patents
Szubsztituált aminpurin vegyületek, ezek összetételei, és az ezekkel végzett kezelések módszereiInfo
- Publication number
- HUE054694T2 HUE054694T2 HUE15848476A HUE15848476A HUE054694T2 HU E054694 T2 HUE054694 T2 HU E054694T2 HU E15848476 A HUE15848476 A HU E15848476A HU E15848476 A HUE15848476 A HU E15848476A HU E054694 T2 HUE054694 T2 HU E054694T2
- Authority
- HU
- Hungary
- Prior art keywords
- compositions
- methods
- aminopurine compounds
- treatment therewith
- substituted aminopurine
- Prior art date
Links
- -1 aminopurine compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462060339P | 2014-10-06 | 2014-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054694T2 true HUE054694T2 (hu) | 2021-09-28 |
Family
ID=55632334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15848476A HUE054694T2 (hu) | 2014-10-06 | 2015-10-05 | Szubsztituált aminpurin vegyületek, ezek összetételei, és az ezekkel végzett kezelések módszerei |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US9512124B2 (enExample) |
| EP (2) | EP3204386B1 (enExample) |
| JP (4) | JP6884701B2 (enExample) |
| KR (2) | KR20230035424A (enExample) |
| CN (2) | CN113248506A (enExample) |
| AR (2) | AR102171A1 (enExample) |
| AU (2) | AU2015328414B2 (enExample) |
| CA (1) | CA2963639C (enExample) |
| CL (1) | CL2017000820A1 (enExample) |
| CO (1) | CO2017003838A2 (enExample) |
| CY (1) | CY1124173T1 (enExample) |
| DK (1) | DK3204386T3 (enExample) |
| EA (1) | EA201790779A1 (enExample) |
| EC (1) | ECSP17026210A (enExample) |
| ES (2) | ES2871142T3 (enExample) |
| HR (1) | HRP20210656T1 (enExample) |
| HU (1) | HUE054694T2 (enExample) |
| IL (2) | IL251566B (enExample) |
| LT (1) | LT3204386T (enExample) |
| MX (2) | MX388321B (enExample) |
| PL (1) | PL3204386T3 (enExample) |
| PT (1) | PT3204386T (enExample) |
| RS (1) | RS61884B1 (enExample) |
| SG (2) | SG11201702759XA (enExample) |
| SI (1) | SI3204386T1 (enExample) |
| SM (1) | SMT202100302T1 (enExample) |
| TW (1) | TW201629063A (enExample) |
| WO (1) | WO2016057370A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230035424A (ko) * | 2014-10-06 | 2023-03-13 | 시그날 파마소티칼 엘엘씨 | 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| EP3233808B1 (en) | 2014-12-16 | 2021-07-14 | Signal Pharmaceuticals, LLC | Medical uses comprising methods for measurement of inhibition of c-jun n-terminal kinase in skin |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| ES2803650T3 (es) | 2015-03-18 | 2021-01-28 | Bristol Myers Squibb Co | Compuestos heterocíclicos útiles como inhibidores de TNF |
| ES2797805T3 (es) | 2015-03-18 | 2020-12-03 | Bristol Myers Squibb Co | Compuestos heterocíclicos tricíclicos sustituidos |
| BR112017019731A2 (pt) | 2015-03-18 | 2018-05-22 | Bristol-Myers Squibb Company | compostos heterocíclicos tricíclicos úteis como inibidores de tnf |
| ES2994877T3 (en) | 2015-07-24 | 2025-02-03 | Celgene Corp | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
| EP3331889B1 (en) | 2015-08-03 | 2020-09-23 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
| BR112018070163A2 (pt) * | 2016-04-01 | 2019-01-29 | Signal Pharm Llc | compostos de aminopurina substituída, composições e métodos de tratamento |
| HRP20211546T1 (hr) * | 2016-04-01 | 2022-01-07 | Signal Pharmaceuticals, Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triklorfenil)amino)-9h-purin-9-il)-1 -metilcikloheksan-1 -karboksamid i postupci njegove uporabe |
| CN109563095B (zh) * | 2016-06-02 | 2021-10-29 | 细胞基因公司 | 动物和人抗疟剂 |
| TW201802093A (zh) * | 2016-06-02 | 2018-01-16 | 西建公司 | 動物及人類抗錐蟲及抗利什曼原蟲藥劑 |
| BR112020006599B1 (pt) | 2017-10-04 | 2024-02-20 | Celgene Corporation | Cápsulas compreendendo cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricl oroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carb oxamida |
| US10590136B2 (en) * | 2017-10-04 | 2020-03-17 | Celgene Corporation | Processes for the preparation of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| CN114478326B (zh) * | 2022-01-21 | 2023-10-03 | 安徽宁亿泰科技有限公司 | 一种苯嘧磺草胺关键中间体的合成方法 |
| CN117964497B (zh) * | 2024-01-26 | 2026-03-31 | 江西凯信生物医药有限公司 | 一种3,3-二氟环戊胺盐酸盐的合成方法 |
| CN121758295A (zh) * | 2024-09-30 | 2026-03-31 | 青岛清原化合物有限公司 | 一种亚氨基芳基类化合物及中间体的制备方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| CZ27399A3 (cs) * | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| US7672705B2 (en) * | 2004-07-19 | 2010-03-02 | Resonant Medical, Inc. | Weighted surface-to-surface mapping |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7521446B2 (en) * | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| JP2009516707A (ja) | 2005-11-18 | 2009-04-23 | アストラゼネカ・アクチエボラーグ | 固形製剤 |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| CN101568544B (zh) | 2006-10-27 | 2016-10-26 | 西格诺药品有限公司 | 包含4‑[9‑(四氢‑呋喃‑3‑基)‑8‑(2,4,6‑三氟‑苯氨基)‑9h‑嘌呤‑2‑基氨基]‑环己烷‑1‑醇的固体形式，其组合物，及其用途 |
| PT2279731E (pt) | 2008-04-23 | 2013-08-30 | Farmasierra Mfg S L | Composição farmacêutica melhorada contendo ibuprofeno e codeína |
| US20130034495A1 (en) | 2009-12-09 | 2013-02-07 | Marie Georges Beauchamps | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| KR20230035424A (ko) | 2014-10-06 | 2023-03-13 | 시그날 파마소티칼 엘엘씨 | 치환된 아미노퓨린 화합물, 그의 조성물 및 그를 사용한 치료 방법 |
| HRP20211546T1 (hr) | 2016-04-01 | 2022-01-07 | Signal Pharmaceuticals, Llc | (1s,4s)-4-(2-(((3s,4r)-3-fluortetrahidro-2h-piran-4-il)amino)-8-((2,4,6-triklorfenil)amino)-9h-purin-9-il)-1 -metilcikloheksan-1 -karboksamid i postupci njegove uporabe |
-
2015
- 2015-10-05 KR KR1020237006598A patent/KR20230035424A/ko not_active Withdrawn
- 2015-10-05 SG SG11201702759XA patent/SG11201702759XA/en unknown
- 2015-10-05 PT PT158484766T patent/PT3204386T/pt unknown
- 2015-10-05 JP JP2017538172A patent/JP6884701B2/ja active Active
- 2015-10-05 EP EP15848476.6A patent/EP3204386B1/en active Active
- 2015-10-05 WO PCT/US2015/053941 patent/WO2016057370A1/en not_active Ceased
- 2015-10-05 SG SG10202009598VA patent/SG10202009598VA/en unknown
- 2015-10-05 ES ES15848476T patent/ES2871142T3/es active Active
- 2015-10-05 LT LTEP15848476.6T patent/LT3204386T/lt unknown
- 2015-10-05 KR KR1020177010551A patent/KR102504849B1/ko active Active
- 2015-10-05 AU AU2015328414A patent/AU2015328414B2/en active Active
- 2015-10-05 CA CA2963639A patent/CA2963639C/en active Active
- 2015-10-05 ES ES20214685T patent/ES2980464T3/es active Active
- 2015-10-05 SI SI201531584T patent/SI3204386T1/sl unknown
- 2015-10-05 TW TW104132732A patent/TW201629063A/zh unknown
- 2015-10-05 SM SM20210302T patent/SMT202100302T1/it unknown
- 2015-10-05 EP EP20214685.8A patent/EP3822274B1/en active Active
- 2015-10-05 PL PL15848476T patent/PL3204386T3/pl unknown
- 2015-10-05 CN CN202110381676.XA patent/CN113248506A/zh active Pending
- 2015-10-05 HR HRP20210656TT patent/HRP20210656T1/hr unknown
- 2015-10-05 DK DK15848476.6T patent/DK3204386T3/da active
- 2015-10-05 CN CN201580065272.2A patent/CN107001372B/zh active Active
- 2015-10-05 MX MX2017004600A patent/MX388321B/es unknown
- 2015-10-05 HU HUE15848476A patent/HUE054694T2/hu unknown
- 2015-10-05 AR ARP150103202A patent/AR102171A1/es not_active Application Discontinuation
- 2015-10-05 EA EA201790779A patent/EA201790779A1/ru unknown
- 2015-10-05 US US14/874,513 patent/US9512124B2/en active Active
- 2015-10-05 RS RS20210632A patent/RS61884B1/sr unknown
-
2016
- 2016-10-27 US US15/335,619 patent/US9737541B2/en active Active
-
2017
- 2017-04-04 IL IL251566A patent/IL251566B/en active IP Right Grant
- 2017-04-04 CL CL2017000820A patent/CL2017000820A1/es unknown
- 2017-04-06 MX MX2021014531A patent/MX2021014531A/es unknown
- 2017-04-20 CO CONC2017/0003838A patent/CO2017003838A2/es unknown
- 2017-04-27 EC ECIEPI201726210A patent/ECSP17026210A/es unknown
- 2017-07-05 US US15/641,383 patent/US10149849B2/en active Active
-
2018
- 2018-10-24 US US16/169,414 patent/US10398700B2/en active Active
-
2019
- 2019-07-17 US US16/514,749 patent/US10646493B2/en active Active
- 2019-10-02 JP JP2019182133A patent/JP6987823B2/ja active Active
-
2020
- 2020-02-28 AU AU2020201486A patent/AU2020201486B2/en active Active
- 2020-04-13 US US16/846,503 patent/US10940152B2/en active Active
- 2020-09-01 IL IL277069A patent/IL277069B/en unknown
-
2021
- 2021-01-12 US US17/147,127 patent/US11590139B2/en active Active
- 2021-05-24 CY CY20211100444T patent/CY1124173T1/el unknown
- 2021-12-01 JP JP2021195105A patent/JP7196270B2/ja active Active
-
2022
- 2022-12-14 JP JP2022199122A patent/JP2023027269A/ja active Pending
-
2023
- 2023-01-11 US US18/095,670 patent/US20230158035A1/en not_active Abandoned
- 2023-03-09 AR ARP230100589A patent/AR128748A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277069B (en) | Modified aminopurine compounds, their compositions and methods of treatment with them | |
| IL262007A (en) | Modified aminopurine compounds, their compositions and methods of treatment using them | |
| HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
| HUE063026T2 (hu) | Eljárások és készítmények LDHA expressziójának gátlására | |
| HUE046756T2 (hu) | Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei | |
| HUE053485T2 (hu) | Készítmények és eljárások meibom-mirigy diszfunkció kezelésére | |
| HUE046000T2 (hu) | Antiproferatív vegyületek és alkalmazásuk módszerei | |
| HUE052373T2 (hu) | Szubsztituált krománok és alkalmazási eljárások | |
| HUE055755T2 (hu) | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk | |
| EP3313404C0 (en) | THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| PL3277270T3 (pl) | Kompozycje i sposoby leczenia niedokrwistości | |
| PL3145522T3 (pl) | Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom | |
| HUE042596T2 (hu) | Tisztítóberendezés és az ehhez tartozó mûködési eljárás | |
| HUE054673T2 (hu) | Rák kezelésére szolgáló eljárások és készítmények | |
| HRP20260361T1 (hr) | Supstituirani 4-fenilpiperidini, njihova priprava i uporaba | |
| HUE054204T2 (hu) | Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez | |
| HUE055357T2 (hu) | Vegyületek kompozíciói és azok alkalmazásai | |
| IL256322B (en) | Improved formulations of deferasirox and methods of making the same | |
| PT3137479T (pt) | Composições de oligonucleótidos e métodos de fabrico das mesmas | |
| EP3212595C0 (en) | EXPLOSIVE COMPOSITION AND METHOD OF IMPLEMENTATION | |
| PL2998311T3 (pl) | Mieszanina alkiloglikozydów, ich wytwarzanie i zastosowanie | |
| IL254825A0 (en) | Methods of treatment with taselisib | |
| PL3250042T3 (pl) | Kompozycja, sposób, zastosowanie i wyrób | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii |